Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC [Phase 1]
A Phase 1 platform trial evaluating novel agents in combination with radiotherapy for non-small cell lung cancer, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Tubeless VATS for Lung Cancer Surgery [NA]
A completed clinical trial evaluating tubeless video-assisted thoracoscopic surgery (VATS) for non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
A phase 2 clinical trial evaluating the combination of amivantamab and lazertinib for metastatic or recurrent non-small cell lung cancer has…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: Toripalimab Combined With SBRT for NSCLC [Phase 2]
Phase 2 trial evaluating toripalimab in combination with stereotactic body radiotherapy for non-small cell lung cancer is active/not recruit…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Epidemiology of Young Lung Cancer - Survey
A clinical trial survey investigating the epidemiology of young non-small cell lung cancer, sponsored by Addario Lung Cancer Medical Institu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Using ctDNA to Determine Therapies for Lung Cancer [Phase 2]
A Phase 2 clinical trial evaluating whether circulating tumor DNA (ctDNA) can guide therapy choices for non-small cell lung cancer. The stud…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SLC-391 in combination with pembrolizumab for non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients [Phase 2]
This clinical trial update reports on a Phase II study evaluating SSGJ-706 as monotherapy and in combination for first-line advanced non-sma…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial of HRS-4508 for locally advanced or metastatic non-small cell lung cancer. The study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of INBRX-106 in combination with pembrolizumab for locally advanced or metastatic sol…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen [Phase 2]
A Phase II clinical trial evaluating radiotherapy followed by durvalumab and ceralasertib in stage III non-small cell lung cancer patients w…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Accelerating Lung Cancer Diagnosis Through Liquid Biopsy
This clinical trial update notes an active-not-recruiting study sponsored by University Health Network in Toronto, investigating liquid biop…
-
FDA approval · 2025-12-17FDA Approved: RYBREVANT FASPRO — Original Application (Janssen Biotech, Inc.)
FDA approved Rybrevant FASPRO, a subcutaneous co-formulation of amivantamab and hyaluronidase-lpuj, under an original application by Janssen…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study [NA]
Pilot study evaluating acupuncture to enhance immunotherapy in advanced non-small cell lung cancer; the trial is currently not recruiting.
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
This clinical trial update describes a study investigating how patients' genomic profiles influence thromboembolic risk in locally advanced …
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity [Phase 2]
Phase 2 clinical trial investigating cabozantinib in RET fusion-positive advanced non-small cell lung cancer and in patients with ROS1, NTRK…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC [Phase 2]
Phase 2 clinical trial evaluating FDG-PET guided small-volume accelerated immuno-chemoradiotherapy for locally advanced, unresectable non-sm…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated [Phase 3]
A Phase 3 trial evaluating tepotinib versus standard treatment in adults with advanced MET exon 14-mutated non-small cell lung cancer that h…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Dupilumab_Metastatic NSCLC [Phase 1, Phase 2]
Clinical trial update indicates a Phase 1/Phase 2 study of dupilumab in metastatic non-small cell lung cancer is currently active but not re…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
A clinical trial is exploring AI-based multimodal data to predict efficacy of targeted therapies in EGFR-mutant non-small cell lung cancer, …
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Lorlatinib Continuation Study [Phase 4]
Pfizer's Lorlatinib continuation study (Phase 4) for Non-Small-Cell Lung Cancer is active but not currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC [Phase 3]
LUNAR-2 is a Phase 3 trial evaluating Tumor Treating Fields (TTFields) with pembrolizumab and platinum-based chemotherapy for metastatic non…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: ROSE for Improved Molecular Marker Testing Via EBUS [NA]
A Johns Hopkins clinical trial is evaluating ROSE-enabled molecular marker testing via EBUS for non-small cell lung cancer and is currently …
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: HC010 in First-line PD-L1 Positive Advanced NSCLC Patients [Phase 2]
Phase 2 clinical trial HC010 is recruiting in first-line PD-L1 positive advanced non-small cell lung cancer patients.
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors [Phase 1]
Clinical trial update for a Phase 1 study evaluating the safety and pharmacokinetics of ADU-1805 in adults with advanced solid tumors; the s…